Site search

JP
EN

Top
Company Profile
Science
- About iPS-NKT
Pipeline
- Overview
- BP2201
- BP2301
- BP1200
- BP1202
- BP1210
- BP1212
- GRN-1201
- BP1209
Presentations
News
Investor Relations

Investor Relations

IR News

2024

2024.11.8Financial Results for the Six Months ended September 30, 2024 [Japanese GAAP] (non-consolidated)（322KB）
2024.8.9Financial Results for the Three Months ended June 30, 2024 [Japanese GAAP] (non-consolidated)（304KB）
2024.5.23Financial Results for the Fiscal Year ended March 31, 2024 [Japanese GAAP] (non-consolidated)（507KB）
2024.3.4Topline Results of Phase I Clinical Trial of iPS-NKT in Patients with Relapsed or Refractory Head and Neck Cancer（186KB）
2024.2.9Financial Results for the Nine Months ended December 31, 2023 [Japanese GAAP] (non-consolidated)（302KB）

2023

2023.11.14Announcement of Issuance of Series 16 Moving Strike Warrants and Unsecured Bonds (Private Placement Bonds: PPB)（499KB）
2023.11.10Financial Results for the Six Months ended September 30, 2023 [Japanese GAAP] (non-consolidated)（315KB）
2023.11.4BrightPath to Update the Preclinical Data of iPSC-derived CAR-iNKT at SITC 2023（162KB）
2023.11.4BrightPath to Update the Preclinical Data of HER2-CAR-T at SITC 2023（105KB）
2023.10.17BrightPath to Update the Preclinical Data of HER2-CAR-T and iPSC-derived CAR-iNKT at SITC 2023（103KB）
2023.8.10Financial Results for the Three Months ended June 30, 2023 [Japanese GAAP] (non-consolidated)（302KB）
2023.5.12Financial Results for the Fiscal Year ended March 31, 2023 [Japanese GAAP] (non-consolidated)（567KB）
2023.5.2BrightPath Biotherapeutics and Artisan Bio Announce Research and Licensing Agreement to Accelerate Development of BrightPath's Novel Allogeneic iPSC Derived Cell Therapy Platform across Multiple Indications（173KB）

2022

2022.11.10BrightPath to Update the Pre-clinical Data of BP1210 and BP1212 at SITC 2022（218KB）
2022.11.10BrightPath to Update the Pre-clinical Data of iPS-NKT at SITC 2022（216KB）
2022.11.10BrightPath to Update the Pre-clinical Data of BP1202 at SITC 2022（324KB）
2022.11.1BrightPath Exercised the Option to Obtain Exclusive Development, Manufacturing and Marketing License for iPS-NKT from RIKEN（131KB）
2022.10.5BrightPath to Update the Pre-clinical Data of iPS-NKT, BP1202 and BP1212 at SITC 2022（321KB）
2022.5.12Announcement of the early termination of a phase II clinical trial of the cancer peptide vaccine GRN-1201 in the United States and Top-line data （254KB）
2022.5.12 Financial Results for the Fiscal Year ended March 31, 2022 [Japanese GAAP]（423KB）
2022.5.9Phase I clinical trial initiated for HER2-targeted CAR-T cell therapy BP2301（225 KB）
2022.4.13BrightPath Presents Preclinical Data on a CD73 antagonist antibody at AACR 2022（214KB）
2022.4.13BrightPath Presents New Data on Personalized Neoantigen Vaccine at AACR 2022（268KB）
2022.4.11BrightPath Presents New Data on Personalized Neoantigen Vaccine at AACR 2022（313KB）
2022.4.11BrightPath Presents New Data on Preclinical Data on BP2301(HER2 CAR-T) at AACR 2022（288KB）

2021

2021.11.12BrightPath to Present Updates on the Pre-clinical Data of BP1210 at SITC 2021（214KB）
2021.9.24BrightPath's abstract on a CD73 antagonist antibody wins Best Poster Award at ESMO 2021（277KB）
2021.5.13 Financial Results for the Fiscal Year ended March 31, 2021 [Japanese GAAP]（445KB）

2020

2020.5.15 Financial Results for the Fiscal Year ended March 31, 2020 [Japanese GAAP]（228KB）

2019

2019.12.24BrightPath Concludes Agreements with Osaka University, BIKEN Foundation and Teikyo University for Development of TLR9 Agonist Lipid-Nucleic Acid as Immuno-stimulator（227KB）
2019.8.19Shinshu University and BrightPath Conclude Joint R&D Agreement for CAR-T Cell Therapy for Solid Tumors（1456KB）
2019.8.9Announcement on the Results of a Phase I Clinical Trial in Melanoma for Cancer Peptide Vaccine GRN-1201（185KB）
2019.5.10 Financial Results for the Fiscal Year ended March 31, 2019 [Japanese GAAP]（347KB）
2019.3.15Announcement on the Waiver of Claims for a Subsidiary, Shift to Non-consolidated Settlement of Accounts, and Disclosure of Forecast for Non-consolidated Financial Results（112KB）

2018

2018.12.19University of Tokyo and BrightPath Conclude Collaborative Research Agreement for Fully Personalized Cancer Immunotherapy（167KB）
2018.11.9 Financial Results for the Second Quarter of the Fiscal Year Ending March 31, 2019 [Japanese GAAP] (Consolidated)（162KB）
2018.10.12Announcement on Dissolution of a Subsidiary（324KB）
2018.8.10 Financial Results for the First Quarter of the Fiscal Year Ending March 31, 2019 [Japanese GAAP] (Consolidated)（143KB）
2018.5.17Announcement on the Results of the Phase III Clinical Trial for Cancer Peptide Vaccine ITK-1 in Patients in Japan with Prostate Cancer（276KB）
2018.5.15 Financial Results for the Fiscal Year ended March 31, 2018 [Japanese GAAP] (Consolidated)（505KB）
2018.3.29Collaborative research agreement concluded with RIKEN on iPS cell-derived NKT cell therapy（801KB）
2018.2.14 Financial Results for the Third Quarter of the Fiscal Year Ending March 31, 2018 [Japanese GAAP] (Consolidated)（395KB）
2018.1.25BrightPath concludes agreement to develop personalized cancer vaccine（322KB）
2018.1.15Mie University and BrightPath Launch New Program for Neoantigen-based Personalized Cancer Immunotherapy（187KB）

2017

2017.11.17Patent Issued in Japan on Method for Reconstructing Immune Function Using Pluripotent Stem Cells（176KB）
2017.11.10 Financial Results for the Second Quarter of the Fiscal Year Ending March 31, 2018 [Japanese GAAP] (Consolidated)（935KB）
2017.10.27Collaborative Research on Fully-personalized Cancer Neoantigen Vaccine（583KB）
2017.8.14 Financial Results for the First Quarter of the Fiscal Year Ending March 31, 2018 [Japanese GAAP] (Consolidated)（805KB）
2017.7.24Patent for rejuvenated antigen-specific T lymphocytes using iPS cells（367KB）
2017.7.20Decision to grant patent for CTL inducer composition by Canadian Intellectual Property Office（633KB）
2017.5.15Decision to Grant a Patent Related to Antigenic Peptides Derived from the T790M Point Mutation of Epidermal Growth Factor Receptor（93KB）
2017.5.12 Financial Results for the Fiscal Year ended March 31, 2017 [Japanese GAAP] (Consolidated)（171KB）
2017.5.12Announcement on the Change of the Corporate Name and Partial Amendment to the Articles of Incorporation（66KB）
2017.2.10 Financial Results for the Third Quarter of the Fiscal Year Ending March 31, 2017 [Japanese GAAP] (Consolidated)（183KB）
2017.1.27Notice of the initiation of a phase II clinical trial of GRN-1201 with the concomitant use of an immune checkpoint antibody against NSCLC in the U.S.（90KB）

2016

2016.12.9IR Information on the Initiation of Neoantigen (Genetic Variant Antigen) Peptide Vaccine Development（1393KB）
2016.11.21Announcement of the Acceptance of the Third Party Allocation of New Shares by Advanced Immunotherapy, Co., Ltd. (Acquisition of the Ownership)（623KB）
2016.11.19 Financial Results for the Second Quarter of the Fiscal Year Ending March 31, 2017 [Japanese GAAP] (non-consolidated)（184KB）
2016.8.15 Financial Results for the First Quarter of the Fiscal Year Ending March 31, 2017 [Japanese GAAP] (non-consolidated)（178KB）
2016.8.9Announcement of Joint Research and Development with Kanagawa Cancer Center（145KB）
2016.7.25Announcement Concerning Development of Immunoassay Procedures Outsourced to GreenPeptide（125KB）
2016.5.13 Financial Results for the Fiscal Year ended March 31, 2016 [Japanese GAAP]（167KB）
2016.5.2Completion of Patient Enrollment in Japanese Phase III Clinical Study on GreenPeptide's Lead Product Candidate ITK-1（86 KB）
2016.2.12 Financial Results for the Third Quarter of the Fiscal Year Ending March 31, 2016 [Japanese GAAP] (non-consolidated)（158KB）

2015

2015.11.13 Financial Results for the Second Quarter of the Fiscal Year Ending March 31, 2016 [Japanese GAAP] (non-consolidated)（162KB）
2015.11.4GreenPeptide Receives Clearance from FDA to Proceed with Phase 1 Clinical Trial for Its Therapeutic Cancer Vaccine GRN-1201（126KB）

Adobe Reader is required to view these PDF files